Chemotherapy-Induced Hair Loss: The Use of Biomarkers for Predicting Alopecic Severity and Treatment Efficacy

Iain S Haslam, Eleanor Smart

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Damage to hair follicles following exposure to toxic chemotherapeutics can cause substantial hair loss, commonly known as chemotherapy-induced alopecia (CIA). Preventive therapies remain limited; however, recent advances in the use of scalp cooling technologies have proved successful in preventing or reducing hair loss in some patients. Further improvements in scalp cooling efficacy and/or development of novel treatments to prevent chemotherapy-induced hair loss are required. To achieve this, post-chemotherapy assessment of hair follicle damage markers, with and without scalp cooling, would provide invaluable mechanistic and prognostic information. At present, the availability of such data is extremely limited. This article describes the potential utility of a combination of biomarkers in assessing drug-induced alopecia and the protective potential of existing or new treatments. A greater understanding of the precise mechanisms of anti-CIA therapies through biomarker analysis would enhance the rationale, use, and development of such treatments.

LanguageEnglish
Pages1-7
Number of pages7
JournalBiomarker Insights
Volume14
DOIs
Publication statusPublished - 17 Apr 2019

Fingerprint

Chemotherapy
Alopecia
Biomarkers
Drug Therapy
Cooling
Scalp
Hair Follicle
Poisons
Therapeutics
Availability
Pharmaceutical Preparations
Technology

Cite this

@article{69f705f4a8b3483e83e5055f4ec131bb,
title = "Chemotherapy-Induced Hair Loss: The Use of Biomarkers for Predicting Alopecic Severity and Treatment Efficacy",
abstract = "Damage to hair follicles following exposure to toxic chemotherapeutics can cause substantial hair loss, commonly known as chemotherapy-induced alopecia (CIA). Preventive therapies remain limited; however, recent advances in the use of scalp cooling technologies have proved successful in preventing or reducing hair loss in some patients. Further improvements in scalp cooling efficacy and/or development of novel treatments to prevent chemotherapy-induced hair loss are required. To achieve this, post-chemotherapy assessment of hair follicle damage markers, with and without scalp cooling, would provide invaluable mechanistic and prognostic information. At present, the availability of such data is extremely limited. This article describes the potential utility of a combination of biomarkers in assessing drug-induced alopecia and the protective potential of existing or new treatments. A greater understanding of the precise mechanisms of anti-CIA therapies through biomarker analysis would enhance the rationale, use, and development of such treatments.",
keywords = "chemotherapy-induced alopecia, hair loss, biomarkers, scalp cooling",
author = "Haslam, {Iain S} and Eleanor Smart",
year = "2019",
month = "4",
day = "17",
doi = "10.1177/1177271919842180",
language = "English",
volume = "14",
pages = "1--7",
journal = "Biomarker Insights",
issn = "1177-2719",
publisher = "Libertas Academica Ltd.",

}

Chemotherapy-Induced Hair Loss : The Use of Biomarkers for Predicting Alopecic Severity and Treatment Efficacy. / Haslam, Iain S; Smart, Eleanor.

In: Biomarker Insights, Vol. 14, 17.04.2019, p. 1-7.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemotherapy-Induced Hair Loss

T2 - Biomarker Insights

AU - Haslam, Iain S

AU - Smart, Eleanor

PY - 2019/4/17

Y1 - 2019/4/17

N2 - Damage to hair follicles following exposure to toxic chemotherapeutics can cause substantial hair loss, commonly known as chemotherapy-induced alopecia (CIA). Preventive therapies remain limited; however, recent advances in the use of scalp cooling technologies have proved successful in preventing or reducing hair loss in some patients. Further improvements in scalp cooling efficacy and/or development of novel treatments to prevent chemotherapy-induced hair loss are required. To achieve this, post-chemotherapy assessment of hair follicle damage markers, with and without scalp cooling, would provide invaluable mechanistic and prognostic information. At present, the availability of such data is extremely limited. This article describes the potential utility of a combination of biomarkers in assessing drug-induced alopecia and the protective potential of existing or new treatments. A greater understanding of the precise mechanisms of anti-CIA therapies through biomarker analysis would enhance the rationale, use, and development of such treatments.

AB - Damage to hair follicles following exposure to toxic chemotherapeutics can cause substantial hair loss, commonly known as chemotherapy-induced alopecia (CIA). Preventive therapies remain limited; however, recent advances in the use of scalp cooling technologies have proved successful in preventing or reducing hair loss in some patients. Further improvements in scalp cooling efficacy and/or development of novel treatments to prevent chemotherapy-induced hair loss are required. To achieve this, post-chemotherapy assessment of hair follicle damage markers, with and without scalp cooling, would provide invaluable mechanistic and prognostic information. At present, the availability of such data is extremely limited. This article describes the potential utility of a combination of biomarkers in assessing drug-induced alopecia and the protective potential of existing or new treatments. A greater understanding of the precise mechanisms of anti-CIA therapies through biomarker analysis would enhance the rationale, use, and development of such treatments.

KW - chemotherapy-induced alopecia

KW - hair loss

KW - biomarkers

KW - scalp cooling

U2 - 10.1177/1177271919842180

DO - 10.1177/1177271919842180

M3 - Article

VL - 14

SP - 1

EP - 7

JO - Biomarker Insights

JF - Biomarker Insights

SN - 1177-2719

ER -